Acquired reactive perforating collagenosis treated with nemolizumab
Authors:
- Shehani T. PereraSPShehani T. Perera
- Sofia VescovacciSVSofia Vescovacci
- Sara Kaye GivensSGSara Kaye Givens
- Marc IngleseMIMarc Inglese
- András SchafferASAndrás Schaffer
- Austinn MillerAMAustinn Miller
Open Access
- 5 January 2026
- journal article
- Published by Elsevier in JAAD Case Reports
- Vol. 69, 201-203
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- A giant variant of acquired reactive perforating collagenosis successfully treated with nemolizumabJournal of the European Academy of Dermatology and Venereology, 2024
- Perforating dermatosis in a patient on haemodialysis successfully treated with nemolizumabClinical and Experimental Dermatology, 2023
- Reactive perforating collagenosis successfully treated with dupilumabAustralasian Journal of Dermatology, 2022
- The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect?Toxins, 2022
- Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical studyClinical and Experimental Nephrology, 2021
- Clinical practice guide for the treatment of perforating dermatosisThe Journal of Dermatology, 2020
- Acquired Reactive Perforating Dermatosis is a Variant of Prurigo NodularisActa Dermato-Venereologica, 2017